Median survival of patients with brain metastases from nonsmall cell lung cancer (NSCLC) is
poor and more effective treatments are urgently needed. We have evaluated the efficacy of …

Introduction The efficacy of high-dose (1250 mg/d) gefitinib for the treatment of
leptomeningeal metastasis in a patient with lung cancer harboring a mutation in the …

Background This phase II, open-label study evaluated the efficacy and safety of erlotinib as
second-line therapy in non-small-cell lung cancer (NSCLC) patients with brain metastases …

Non-small cell lung cancer (NSCLC) harboring an activating epidermal growth factor
receptor (EGFR) mutation shows good and rapid response to EGFR tyrosine kinase …

Purpose Brain metastasis (BM) is a leading cause of death from non–small-cell lung cancer
(NSCLC). Reasoning that activation of the epidermal growth factor receptor (EGFR) …

Brain metastases are a common and devastating consequence of disease progression in
patients with non–small cell lung cancer (NSCLC). The epidermal growth factor receptor …

Purpose: Gefitinib and erlotinib can penetrate into the central nervous system (CNS) and
elicit responses in patients with brain metastases (BM) from non–small cell lung cancer …

It has been demonstrated that erlotinib is effective in treating patients with brain metastasis
from non‑small‑cell lung cancer. However, the number of studies determining the erlotinib …

Purpose Recent reports indicate that refractory central nervous system (CNS) metastases of
non-small cell lung cancer (NSCLC) are improved by high-dose gefitinib or erlotinib …

Purpose/Objectives Radiation therapy (RT) is the principal modality in the treatment of
patients with brain metastases (BM). However, given the activity of EGFR tyrosine kinase …